Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Acute Lymphoblastic Leukemia or Aggressive Lymphoma With Relapse in Central Nervous System With Depocyt

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* proven diagnosis of ALL or very aggressive Non-Hodgkin-Lymphoma (Burkitt/Burkitt-like) and CNS relapse~* CNS involvement demonstrated by a positive ventricular or lumbar CSF cytology or characteristic signs and symptoms of neoplastic meningitis plus an MRI or CT scan indicating the presence of meningeal involvement~* in combined relapse in CNS and other locations: systemic therapy with CNS active drugs can be postponed for at least 2 weeks~* Karnofsky Performance Score is \> or = 60%~* 18 years of age or older~* free of uncontrolled infection~* recovered from any grade III / IV toxicities attributable to prior treatment with the exception of hematotoxicity~* patient not pregnant or breast feeding and effective methods to prevent pregnancy~* free from severe heart, lung, liver or kidney dysfunction~* written informed consent~Exclusion Criteria:~* failed to respond (as defined by no clearance of the CSF) to \> 1 dose of prior i.th. MTX or ARAC or triple therapy~* history of neurotoxicity (grade III - IV) attributed to i.th. or systemic HD therapy with MTX or ARAC~* prior CNS relapse \< 1 month before

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Only 1 arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).